KRAS and neoplasm: Restricting analysis to the 92 patients who received cetuximab combinations as salvage therapy, none of the 32 patients with a KRAS-mutant tumour responded to treatment, whereas objective responses occurred in 14 of 60 (23%) patients whose tumors harboured only WT KRAS alleles (P=0.002).